HC Wainwright Analysts Lower Earnings Estimates for ANRO

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Equities research analysts at HC Wainwright cut their Q2 2025 EPS estimates for Alto Neuroscience in a report released on Tuesday, May 20th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.50) per share for the quarter, down from their prior estimate of ($0.48). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.54) per share. HC Wainwright also issued estimates for Alto Neuroscience's Q3 2025 earnings at ($0.71) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.48) EPS, Q1 2026 earnings at ($0.82) EPS, Q2 2026 earnings at ($0.84) EPS, Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($0.67) EPS, FY2026 earnings at ($3.15) EPS, FY2027 earnings at ($3.15) EPS, FY2028 earnings at ($3.06) EPS and FY2029 earnings at ($1.72) EPS.

A number of other analysts have also recently commented on the stock. William Blair reaffirmed an "outperform" rating on shares of Alto Neuroscience in a research report on Friday, March 21st. Wedbush reissued a "neutral" rating and set a $4.00 price objective on shares of Alto Neuroscience in a research report on Thursday, May 15th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $15.40.

Alto Neuroscience Trading Down 3.0%

ANRO traded down $0.09 during trading on Thursday, reaching $2.94. 59,493 shares of the stock traded hands, compared to its average volume of 385,061. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $79.59 million, a PE ratio of -1.26 and a beta of 1.87. The stock's 50-day moving average is $2.35 and its 200 day moving average is $3.38. Alto Neuroscience has a 12 month low of $1.60 and a 12 month high of $17.55.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.06.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently made changes to their positions in ANRO. Armistice Capital LLC raised its holdings in shares of Alto Neuroscience by 146.2% in the 1st quarter. Armistice Capital LLC now owns 1,600,000 shares of the company's stock worth $3,456,000 after acquiring an additional 950,000 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Alto Neuroscience in the 4th quarter worth about $3,542,000. Point72 Asset Management L.P. raised its holdings in shares of Alto Neuroscience by 73.1% in the 4th quarter. Point72 Asset Management L.P. now owns 1,692,153 shares of the company's stock worth $7,158,000 after acquiring an additional 714,461 shares during the last quarter. Woodline Partners LP raised its holdings in shares of Alto Neuroscience by 397.6% in the 4th quarter. Woodline Partners LP now owns 621,976 shares of the company's stock worth $2,631,000 after acquiring an additional 496,976 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Alto Neuroscience by 198.1% in the 4th quarter. Northern Trust Corp now owns 587,135 shares of the company's stock worth $2,484,000 after acquiring an additional 390,190 shares during the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.